Gene therapy specialist Meiragtx Holdings plc got a market bump courtesy of newly released top-line data from its phase II bridging study in Parkinson’s disease. The six-month, three-arm randomized, double-blind, sham controlled trial of AAV-GAD, a one-time infusion, demonstrated significant and clinically meaningful improvements in key efficacy endpoints. The primary objective was evaluating the therapy’s safety and tolerability. The study of participants with idiopathic disease showed the therapy was safe and well-tolerated with no serious adverse events. Meiragtx is pursuing approvals in the U.S., Europe and Japan.
Meiragtx looks to a phase III in Parkinson’s - Cure Parkinson's
Meiragtx looks to a phase III in Parkinson’s
Written by
Farooqji
To view profiles and participate in discussions please or .
Read more about...
2 Replies
•
Not what you're looking for?
You may also like...
Annovis Bio Releases Promising Phase III Parkinson’s Data
https://www.globenewswire.com/news-release/2024/07/02/2907365/0/en/Annovis-Bio-Announces-New-Data-fr
Bummer. Isradipine fails in Phase III Trial.
Long-term use of blood pressure medication Dynacirc (isradipine) does not slow disease progression...
Phase III Inosine Trial to Slow Parkinson's Now Recruiting around The United States
This is one of the few possible neuroprotective trials for early stage Parkinson's and they are...
Phase 2 Mesenchymal Stem Cell Trial in USA
"A newly opened Phase 2 clinical trial is evaluating adult stem cells as a potentially...
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
"When we reached the point of unblinding the data for the PD Phase III study, we discovered an...